Cost-effectiveness of bladder cancer screening

Yair Lotan, Robert S. Svatek

Producción científica: Review articlerevisión exhaustiva

2 Citas (Scopus)


Bladder cancer is the fourth most common cancer in men and 25% of patients present with advanced disease resulting in a poor prognosis. Urine-based tests, including evaluation for blood in the urine or tumor markers, may allow early detection of cancer with resultant improved survival. Studies need to be performed to evaluate the feasibility and cost-effectiveness of screening high-risk populations such as smokers.

Idioma originalEnglish (US)
Páginas (desde-hasta)627-632
Número de páginas6
PublicaciónExpert Review of Pharmacoeconomics and Outcomes Research
EstadoPublished - dic 2007
Publicado de forma externa

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy


Profundice en los temas de investigación de 'Cost-effectiveness of bladder cancer screening'. En conjunto forman una huella única.

Citar esto